Status:
COMPLETED
The Effects of a Nurse-led MHealth Program for Symptom Self-management of Breast Cancer Patients Undergoing Chemotherapy
Lead Sponsor:
The Hong Kong Polytechnic University
Collaborating Sponsors:
Ruijin Hospital
Conditions:
Breast Cancer
Chemotherapeutic Toxicity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Breast cancer (BC) survivors will experience multiple symptoms following chemotherapy. During the pandemic of COVID-19, the closure of clinics and fear of infection lead to BC patients' challenges in ...
Detailed Description
This nurse-led mHealth symptom self-management program is composed of one core intervention 'mChemotherapy', one pre-chemotherapy consultation, and two follow-up visits. mChemotherapy will be specific...
Eligibility Criteria
Inclusion
- People who are 18 years or above
- Newly diagnosed with breast cancer
- Commencing chemotherapy and being prescribed with four cycles of a chemotherapy regimen
- Mobile phone and WeChat® users (a mobile application of Shenzhen city's Tencent computer system Co. Ltd.)
- Wi-Fi or 4G network users
- Able to read and write Chinese
Exclusion
- People who are pregnant
- Have been diagnosed with terminal-stage breast cancer (i.e., stage IV)
- Have a history of chemotherapy
- Have been prescribed with targeted therapy within three weeks of completing the chemotherapy
- Have documented mental disorders
- Have already engaged in other mHealth studies
Key Trial Info
Start Date :
May 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 23 2023
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT05192525
Start Date
May 16 2022
End Date
August 23 2023
Last Update
October 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China